Asahi Chemical has reported that sales for the fiscal year ending March fell 5.8% to 936.7 billion yen ($9.1 billion), due to decreases in sales volume and exports.
Net profits were 10.2 billion yen, down 32.7% on the previous year, and operating profits decreased by 42.4% to 22.6 billion yen compared to the previous financial year. For the pharmaceutical division, exports showed a big decrease from 8.2 billion yen to 5.1 billion yen, mainly due to a drop in exports of Elcitonin (elcatonin) to Italy. Bulk sales of antibiotics also decreased. Asahi's best-performing drug Bredinin (mizoribine) gained an additional indication in rheumatoid arthritis and saw sales increase from 2.7 billion yen to 6.1 billion yen as a result.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze